“Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial Participation
Amid the exciting advances at ASCO 2026, there came a “sobering moment” regarding the U.S.’s role as a cancer clinical trial leader, says Robert A. Winn, MD. He discusses what this means for cancer centers going forward with Robert A. Figlin, MD.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Oncology News Central Peer-Spectives
Is It Time for a New Type of Cancer Physician?
What the “Tsunami” of Cancer Survivors Means for Oncologists
“A Lot More Asymptomatic Cancer Out There”: Major MCED Trial Hints at Complicated Future
“The Ever-Shifting and Chaotic” State of CLL Care: What New Data Mean for Practice
Get summaries like this every morning.
Free AI-powered recaps of Oncology News Central Peer-Spectives and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.